However, investors holding on to Tenet's stock under the assumption the company will be bought out at a notable premium may need to reconsider, at least according to KeyBanc Capital Markets' Jason Gurda.
It is "unlikely" that Tenet Healthcare will sell itself given a high level of debt and lack of interest among potential strategic buyers, Gurda commented in a research report (see his track record here). At a $16 billion enterprise valuation, there are few companies that can even afford the price tag for a slow growth hospital company with possible exceptions being HCA Healthcare Inc HCA and maybe Universal Health Services, Inc. UHS.
However, HCA's M&A activity has historically focused on expanding in specific geographic regions and buying Tenet Healthcare would result in a significant overlap in several markets, the analyst noted. Also, Universal Health Services may not have an appetite for new M&A deals after adding new debt to its balance sheet.
But what Tenet Healthcare could reasonably oversee to create value for investors is divesting individual hospitals and/or its Conifer subsidiary. Either action would be accretive to Tenet Healthcare's stock and accelerate de-leveraging.
However, it is unclear at this point "how far management is willing to go in breaking up the business."
Related Links:Wall Street's M&A Chatter From September 13: Tenet, Potash, Oclaro, Lattice Semiconductor
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.